The Foundation Board of the Fonds fuer versuchstierfreie Forschung (FFVFF, now Animalfree Research) established an annual award for the best article published in ALTEX in 1997. ALTEX Edition, founded in 2006, continues to bestow the award annually.

The Doerenkamp-Zbinden Foundation has generously sponsored the ALTEX Prize, which entails a personal prize of CHF 2.000, since 2014.

The members of the Board of ALTEX Edition, the ALTEX Editorial Board and ALTEX Editorial Office elect the winner of the annual award out of all main articles published in the previous year; articles including members of the Board of ALTEX Edition or ALTEX Editorial Office as first authors are excluded. Members of the Board of ALTEX Edition and ALTEX Editorial Office may not vote for papers on which they themselves are co-authors.

The award is presented to the first author of the article at an international conference.

 

ALTEX Prize Winners

2023
Ans Punt et al., Wageningen Food Safety Research, Wageningen, The Netherlands 
Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data
ALTEX 39, 221–234

2022
Wanda van der Stel et al., Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands 
New approach methods (NAMs) supporting read-across: Two neurotoxicity AOP-based IATA case studies
ALTEX 38, 615–635.

2021
Taylor Rycroft et al., Environmental Laboratory, U.S. Army Engineer Research and Development Center, Vicksburg, MS, USA
AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways
ALTEX 37, 64-74.

2020
Pilar Prieto et al., EU Commission Joint Research Centre (JRC), Ispra, Italy
Investigating cell type specific mechanisms contributing to acute oral toxicity
ALTEX 36, 39-64.

2019
Fabian Grimm et al., formerly Texas A&M University, now ExxonMobil Biomedical Sciences, Inc.
A human population-based organotypic in vitro model for cardiotoxicity screening
ALTEX 35, 441-452.

2018
Martin Paparella et al., Medical University Innsbruck, Austria
Uncertainties of testing methods: What do we (want to) know about carcinogenicity?
ALTEX 34, 235-252.

2017
Uwe Marx et al., TissUse GmbH, Berlin, Germany
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.
ALTEX 33, 272-321.

2016
Heike A. Behrensdorf-Nicol et al., Paul-Ehrlich Institute, Langen, Germany
“BINACLE” assay for in vitro detection of active tetanus neurotoxin in toxoids.
ALTEX 32, 137-142.

2015
Sarah E. Cavanaugh et al., Physicians Committee for Responsible Medicine, Washington, D.C., USA
Animal models of Alzheimer disease: historical pitfalls and a path forward.
ALTEX 31, 279-302.

2014
Miriam N. Jacobs et al., European Food Safety Authority, Parma, Italy
In vitro metabolism and bioavailability tests for endocrine active substances: What is needed next for regulatory purposes?
ALTEX 30, 331-351.

2013
Fransisca Leonard et al., Saarland University, Saarbruecken, Germany
Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model.
ALTEX 29, 275-285.

2012
Erwin van Vliet, CAAT, Johns Hopkins University, Baltimore, USA
Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century.
ALTEX 28, 17-44.

2011
Phillip B. Kuegler, Doerenkamp-Zbinden Chair for in vitro toxicology and Biomedicine, University of Konstanz, Germany
Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing.
ALTEX 27, 17-42.

2010
Costanza Rovida, Private Consultant, Varese, Italy
Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the Transatlantic Think Tank for Toxicology (t⁴).
ALTEX 26, 187-208.

2009-1
Thomas Hartung, CAAT, Johns Hopkins University, Baltimore, USA
Food for thought …. on animal tests.
ALTEX 25, 3-9.

2009-2
Marcel Leist, Doerenkamp-Zbinden Chair for in vitro toxicology and Biomedicine, University of Konstanz, Germany
The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.
ALTEX 25, 163-190.

2008
Marie-Jeanne W. A. Schiffelers et al., Utrecht University, Utrecht School of Governance (USG), The Netherlands
Factors stimulating or obstructing the implementation of the 3Rs in the regulatory process.
ALTEX 24, 271-278.

2007
Arianna Ferrari, Technical University of Darmstadt, Darmstadt, Germany
Genetically modified laboratory animals in the name of the 3Rs?
ALTEX 23, 294-307.

2006
Marion Krug et al., Paul-Ehrlich Institute, Langen, Germany
Serological test methods as replacement for infection trials in piglets to test the potency of E. coli vaccines for sows (dams).
ALTEX 22, 111-116.

2005
Mahtab Bahramsoltani and Johanna Plendl, Free University, Berlin, Germany
Ein neues in vitro Modell zur Quantifizierung der Angiogenese.
ALTEX 21, 227-244.

2004
Oliver Reuthebuch et al., University Hospital, Zurich, Switzerland
Vollsynthetisches Trainingsmodell für die Koronarchirurgie: die Abkehr von Tierversuchen?
ALTEX 20, 17-20.

2003-1
Nina Schweigert et al., EAWAG, Swiss Federal Institute for Environmental Science and Technology, Duebendorf, Switzerland
Ecotoxicological assessment of surface waters: a modular approach integrating in vitro methods.
ALTEX 19, Suppl., 1, 30-37.

2003-2
Heinrich W. Grosse, Pastoralsoziologisches Institut (PSI) der Evangelischen Fachhochschule Hannover, Germany
Christliche Verantwortung und Experimentelle Medizin. Versuche mit und am Menschen, Tierversuche.
ALTEX 19, 195-202.

2002
Christiane Gindorf et al., Across Barriers GmbH, Saarbruecken, Germany
Markertransport über biologische Barrieren in vitro: Vergleich von Zellkulturmodellen für die Dünndarmschleimhaut, die Blut-Hirn Schranke und das Alveolarepithel der Lunge.
ALTEX 18, 155-164.

2001
Cornelia B. Reininger Vascular Center, University of Munich, Germany
The cell function analyser (CFA) – a physiological in vitro vascular model and potential alternative to animal experiments.
ALTEX 17, 115-125.

2000
Guntolf Herzberg, Berlin, Germany
Was kann „ethisches Abwägen“ im Tierversuch bedeuten?
ALTEX 16, 255-266.

1999
No award

1998
Elvira Ebert et al., Paul-Ehrlich Institute, Langen, Germany
Serologische Wirksamkeitsprüfung von Clostridium perfringens-betatoxoidhaltigen Veterinärimpfstoffen - eine Alternative zum gesetzlich vorgeschriebenen Mäuseneutralisationstest.
ALTEX 13, 68-75.
Optimierung und Etablierung von serologischen Methoden für die Wirksamkeitsprüfung von Immunglobulinen gegen Clostridium tetani-Toxoid.
ALTEX 15, Suppl., 30-32.
Entwicklung und Prävalidierung yon Alternativmethoden zur Wirksamkeitsprüfung von Clostridium perfringens-Impfstoffen.
ALTEX 15, Suppl., 59-61.